Antiviral treatment analysis

Antiviral therapy is chronic hepatitis b (CHB) key treatment strategy. Near 10  year long-acting interferons, lamivudine, adefovir dipivoxil, entecavir, for the beef and other drug research and development, provides new tools for hepatitis b treatment, use of antiviral drugs has been shown to reduce the incidence of cirrhosis, liver cancer. However these treatments is not completely clear the HBV,  HBV  cannot be solved; problems of persistent infections.　　　Authors according to their own clinical experience, analysis of current antiviral therapy for chronic hepatitis b status and difficult problems.　　　Status for patients with newly diagnosed hepatitis-b, optional treatment has two main programmes. Is interferon treatment, treatment is limited, its long-term clinical benefits have been verified, but there are still more drug side effects, problems of HBeAg serological conversion rate is not high. Second, nucleoside (acid) analogues, most patients are able to obtain good virological response, but need long-term medication, HBeAg serological conversion rate is not high, may lead to rebound after the withdrawal.　　　Now believe, serological conversion does not occur in patients with HBeAg-positive and HBeAg-negative hepatitis b patients need long-term use of nucleoside (acid) analogues, long-term medication can lead to resistance occurrence probability increases, brings new difficulties to clinical treatment.　　　Difficult mass antiviral drug for hepatitis b patients in recent 10 years, in addition to the emphasis on optimization of initial treatment in patients with treatment, the following situations will increasingly become the clinical treatment of difficulty. First, a large number of patients with refractory patients with hepatitis b will gradually become the main crowd   such as initial treatment for poor, stop the illness after repeated re-treatment of refractory chronic hepatitis b is the hard part.　　　After the initial treatment of patients with HBeAg-positive serological conversion HBeAg is available not only to the 30%; sequential monotherapy treatment led to multiple drug-resistant; treatment in patients with HBeAg-negative uncertainty, disease-prone rebounded after the withdrawal.　　　Secondly, the compensation period and antiviral treatment in patients with decompensated cirrhosis   mostly in patients with chronic hepatitis b transmission in China, the course of persisting with varying degrees of hepatic cirrhosis, seriously affecting the quality of life and become my liver, slow rush of severe hepatitis and liver failure, liver disease-related death of important reasons.　　　Finally, occult antiviral treatment for chronic hepatitis b   according to the report of investigation on HBsAg-negative people in different regions of China show that these populations HBV DNA positive rates as high as 5%. Studies have shown that clinically, obscure and unknown causes of cirrhosis, liver cancer hepatic dysfunction, of latent chronic hepatitis b, 30%, 20%. Probability of occult hepatitis b slow progress to cirrhosis over 50%, and associated with liver cancer. Thus reflects the occult slow hepatitis b clinical importance.